Clinical data guidelines and regulations of the local Ethics Committee and Helsinki Declaration in 1975 were followed during collection and use of DNA samples. At blood collection patients gave their informed consent for the future use of their anonymized DNA.
INTRODUCTION
Crohn's disease (CD) and ulcerative colitis (UC) repre sent the two most common forms of inflammatory bowel diseases (IBD). IBDs are complex diseases with suspected genetic and environmental etiology. Several IBDassociated genes were identified. Interleukin23 receptor (IL23R) is one of those genetic factors found by genomewide association studies (GWAS) [1] . Various studies suggest that the IL23Th17 cellaxis plays an important role in the pathogenesis of IBDs.
IL23R is the human gene of the IL23receptor located on chromosome 1p31 [2] . IL23R is expressed by CD4+ T cells, monocytes/macrophages, and CD11c+ dendritic cells (DCs) [3] . IL23 is a proinflammatory cytokine belonging to the Interleukin 12family [4] . It is a heterodimer consisting of subunit p19 (IL23A), and p40, a subunit of IL12B [5] . IL23 is mainly produced by activated macrophages and DCs [4] . Th17 cells differentiate from naive CD4+ Th cells under the influence of transforming growth factor beta (TGFβ) and IL6 [6] . This can happen in a concentration dependent manner. In a low concentration, TGFβ has synergistic effects with IL6 and IL21, which results in the induction of retinoid orphan nuclear receptor gamma t (Rorγt) and an increase of IL23, as well as promoting the differentiation into Th17 cells. In a high concentration, as well as in combination with IL2, TGFβ decreases the IL23level, and raises the forkhead box protein transcription factor 3level (Foxp3), which is a master regulator in the differentiation of regulatory T cells (Treg) . This leads to the conclusion that there might exist a fluid balance between Th17 and Treg cells [7] . Pathogenic Th17 cells seem to play an important role in autoimmunity. Overexpression of Th17associated cytokines in the bowel tissue of IBD patients was proven [8] . IL17, a proinflammatory cytokine produced by Th17 cells, is produced under the influence of IL23 [6, 7] . It activates stromal and epithelial cells, which results in the excretion of cytokines and chemokines for chemotaxis of neutrophil leukocytes [9] . These pathways make IL23R a potential target in the treatment of various autoimmune inflammatory diseases. Ustekinumab and briakinumab, antibodies against the p40 subunit (IL12 and IL23) already demonstrated therapeutic efficiency in psoriasis, as well as in CD [1012] . An IL12 antibody was able to induce remission in CD [13, 14] . Duerr et al [1] were the first who identified IL23R
as a gene associated with IBDs. They were able to provide evidence for an association in nonJewish UC population.
In a big German cohort Glas et al [4] investigated interactions of IBD genes and the influence of IL23R on the phenotype. All of observed IL23R gene variants, showed a strong association to CD and a weaker association to UC. Nevertheless, eight out of ten single nucleotide polymorphisms (SNPs) showed significant association with UC. The fact that these SNPs were either protective or susceptible in both CD and UC suggests similar diseasemodifying effects. Rs7517847 was the SNP with the strongest association to, and the only independent risk factor of UC. The SNP with the strongest association to CD (rs1004819) was analyzed for phenotypic correlation. Though the TT homozygous carriers showed more frequently ileal involvement and stenosis, it did not reach significance. Rs7517847 did not show any specific influence on the phenotype of UC. There was no evidence for epistasis between the IL23R, and three other IBD genes CARD15/NOD2, SLC22A4 and SLC22A5. Genegene interactions seemed to influence the phenotype but didn't reach statistical significance [4] . Hayatbakhsh et al [15] were able to connect the presence of rs7517847 in UC patients with two main clinical manifestations: blood in the stool and bowel movements. In a Jiangsu Han population the SNP rs17375018 with the G allele was correlated with mild activity in UC [16] . Recent studies also suggest the SNPs of IL23R to be a predictive factor of response to the therapy, e.g., nonresponse to mesalazine and corticosteroids as well as higher response rate for azathioprine and infliximab [17, 18] . The aim of our present study was to investigate the association of seven SNPs of IL23R (rs11209026, rs10889677, rs1004819, rs2201841, rs7517847, rs10489629, rs7530511) with the clinical picture of UC in Hungarian patients diagnosed with UC. 
MATERIALS AND METHODS

Patients
(rs11209026) and SspI (rs10489629). The amplicon contained an obligate cleavage site of the restriction enzyme for the suitable visual control of the efficacy of the digestion. The restriction fragments were separated by electrophoresis on 3% agarose gels containing ethidium bromide, and visualized by UV transillumination.
Statistical analysis
The investigated phenotypic parameters included severity (age of manifestation, extension, frequency of relapse, blood in stool, bowel movements), compli cations (fever, weight loss, anemia, iron deficiency, hypoalbuminemia, need for operation), extraintestinal manifestation (in eyes, joints, skin), medication (aminosalicylate, azathioprine, corticosteroids), as well as familial cases of IBDs and colorectal cancer.
For the age of manifestation, three groups were formed analogous to the Montreal classification of CD (group 1: younger than 17 years, group 2: age between 17 and 40 years, group 3: older than 40 years). The extension of the disease along the colon was defined accordingly to the Estages of the Mon treal classification for UC (E1: involvement limited to the rectum, E2: involvement limited to distal of splenic flexure, E3: involvement extends to proximal to the splenic flexure) [19] . For analyzing the frequency of bowel movements, the patients were divided in three groups (group 1: one up to three a day, group 2: four up to ten a day, group 3: more than ten a day).
Data were examined for independence. Null hypo thesis was formulated as follows: the phenotype of UC is independent of the genotype of IL23R.
22.0 (SPSS Inc., Chicago, IL, United States). P values below 0.05 were considered statistically significant. In this case null hypothesis was rejected.
RESULTS
The frequencies of the genotypes and alleles are shown in Table 1 .
At the investigation of rs11209026, out of 114 subjects 109 (95.6%) carried the wild type (GG), while 5 (4.4%) were heterozygous (GA). The AA homo zygous variant did not appear in this population. That is not surprising, considering a mean allele frequency of A = 0.0219. Regarding the low number of the SNP no significant results could have been expected.
For rs1004819, out of 129 subjects, 52 (40.3%) were wild type carriers (GG), while 68 (52.7%) carried the heterozygous (GA) and 9 (7%) the homozygous (AA) variant. For this polymorphisms no significant results were observed.
Out of 129 patients, 58 (40.0%) were carrier of the wild type (TT) of rs2201841, 60 (46.5%) carried the heterozygous (TC) and 11 (8.5%) the homozygous (CC) variant. Three characteristics reached level of significance: MontrealClassification, appearance of iron deficiency and need for surgery ( Figure 1 ). The MontrealClassification and iron deficiency reached significance for the total distribution (Wt + Hz + Ho). Heterozygous carriers had significant higher risk to require surgery compared to the wild type (P = 0.0348, OR = 8.0). The distribution of the Montreal Classification is shifted to greater extension for carriers of the heterozygous variant. Total distribution reached level of significance (P = 0.0084). This was verified by comparison of the obtained and expected values. The significance was mainly caused by the heterozygous TC variant (P = 0.0429).
Carriers of the rs2201841 had significant higher risk for iron deficiency (P = 0.0299). When Hz and Ho SNPs were combined and compared with the Wt, no significance was observed (P = 0.7476). Statistically significance was found when Wt and Hz SNPs were merged and compared with the Ho variant (P = 0.0388, OR = 6.1837). Surgery was more frequently needed for heterozygous carriers of rs2201841 (P = 0.0348, OR = 8.0). The homozygous form seemed to have no influence on the need for operations.
Out of 112 patients, 40 (35.7%) carried the wild type (TT), 56 (50%) the heterozygous (TG) and 16 (14.3%) the homozygous (GG) rs7517847 SNP. Frequency of bowel movements was significant (P = 0.0078). If instead of three (< 4, 410, > 10) just two groups were used (< 3 and > 3 defecations per day), the distribution was still significant (P = 0.0358). If homozygous and heterozygous SNP were added together and compared to the wild type, no significant difference was found (P = 0.0634). Significance was caused by the heterozygous variant compared to the wild type (P = 0.0050). The rs7517847 seems to have 2 × 3 or 3 × 3 contingency tables were created depending on the attribute. For characteristics that were tested for presence or lack of presence, 2 × 3 contingency tables were created. For characteristics divided in three subsets such as age of onset, Montrealclassification, frequency of relapse and bowel movements, 3 × 3 contingency tables were generated. Genotype was partitioned into wild type (Wt), hetero zygous (Hz) and homozygous (Ho) susceptible SNP.
The distribution was tested in total (wild type + heterozygous + homozygous) as well as separated and Out of 127 patients 44 (34.6%) carried the wild type (GG), 67 (52.8%) the heterozygous (GA) and 16 (12.6%) the homozygous (AA) variant of rs10489629 SNP. Total distribution (Wt + Hz + Ho) of the Montreal Classification was significant (P = 0.0405). Carrying the Hz and Ho SNP alone didn't reach level of signifi cance. Carriers of the heterozygous variant had a higher risk for an extended disease (P = 0.0284). For weight loss significance was observed (P = 0.035). If wild type was compared with heterozygous and homozygous SNP together (Hz + Ho) significance was reached (P = 0.0169, OR = 0.3394). The homozygous variant showed significance (P = 0.0457, OR = 0.1244). Patients who carried the heterozygous susceptible SNP had numerous but statistically not significant lower risk of weight loss (P = 0.0652).
In the case of rs10889677 SNP, out of 112 patients, 51 (45.5%) carried the wild type (CC), 53 (47.3%) the heterozygous (CA) and 8 (7.1%) the homozygous (AA) variant. Carriers of the susceptible SNP needed more frequently azathioprine treatment (P = 0.0285). If wild type was compared with the heterozygous and homozygous SNP, level of significance was found (P = 0.0136, OR = 5.8732). The heterozygous variant also leads to a higher risk for need for surgery (P = 0.0347, OR = 8.0).
Summarized four out of seven SNPs had a statis tically significant influence on the phenotype of UC. The results are shown in Table 2 .
The rs2201841 showed higher stage of extension along the colon (P = 0.0084). The CC homozygous carriers had a higher risk for iron deficiency (P = 0.0388, OR = 6.183). Patients with the heterozygous genotype needed more often operation (P = 0.0348, OR = 8.0).
Patients with the rs7517847 GT heterozygous variant suffered less from bowel movements (P = 0.005).
The rs10489629 SNP in heterozygous form was connected to greater colonic extension (P = 0.0405). Both the heterozygous and homozygous from this variant were associated with lower risk of weight loss (P = 0.0169, OR = 0.3394). In case of rs10889677, therapy with azathioprine was more often necessary for patients carrying the heterozygous and the homo zygous SNP (P = 0.0116, OR = 6.1707). Heterozygous carriers showed higher risk for the need of operations (P = 0.0347, OR = 8.0).
The reason for the statistical significance only to appear for the heterozygous genotype in some cases can be attributable to low numbers of homozygous carriers.
The variants rs11209026, rs1004819, and rs7530511 had no statistical significant influence on the phenotype of UC.
DISCUSSION
Several recent studies suggest IL23R to be a suspect in the pathogenesis of diverse autoimmune dise ases such as IBDs [1, 4, 2025] , psoriasis [11, 22, 26] , Graves disease [27] , ankylosing spondylitis [28, 29] , and rheumatoid arthritis [26, 2931] . Previous investigations in Hungarian populations verified IL23R to play a role in the develop ment of UC [25, 32] . The present study demonstrated the correlation between the SNPs of IL23R, and the phenotype of UC.
Two of the susceptible SNPs for the development of UC (rs2201841, rs10889677) seem to shift the clinical picture from mild into more severe. The rs10889677 was associated with azathioprinetherapy, suggesting the patients to be refractory to 5aminosalicylicacid (5ASA). These results are analogous to the findings of Cravo et al [18] . Interestingly one riskpolymorphism (rs10489629) had riskconferring (greater extension), and protective features (lower risk of weight loss). The reason for the protective and harming character of rs10489629 remains unclear. A possible connection could be a more frequent need for steroids because of the greater extension of the disease along the colon, leading to a lower risk for weight loss. This study did investigate the need for corticosteroids but not the administration frequency. No significant higher need for steroids could been shown. The rs7517847 variant showed a protective character (less bowel movements). Rs7517847 has shown to protect the individual from acquiring the disease [4] , assuming a general protective character of this polymorphism.
An Iranian study (Hayatbakhsh et al [15] , 2012) demonstrated the protective influence of rs7517847 on bowel movements, and blood in stool, the two important features of UC. We were partly able to reproduce these results for the examined Hungarian population. The rs1004819 showed no influence on these characteristics, neither in the Iranian nor the present study. Chinese research detected similar results suggesting the rs17375018 SNP to have a protective character [20] . There are studies that suggest IL23R to be a risk factor for the development of extraintestinal manifestations [18] . This was not reproducible in our study with Hungarian UC patients. The data of the present study are in contrast to the results of Duerr et al [1] and Glas et al [4] , who did find an association between IL23R and inflammatory bowel diseases but no influence on the phenotype of ulcerative colitis.
More studies are necessary to clarify the exact role of IL23R in the development of IBDs, as well as other autoimmune diseases, to improve the knowledge about their pathogenesis and pathophysiology. This may allow individual risk stratification, individual pharmacotherapy, and new approaches for medication with targeted therapy.
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COMMENTS
Background
Inflammatory bowel diseases (IBD) are complex diseases with suspected genetic and environmental etiology. Interleukin-23 receptor (IL23R) is one of those genetic factors found by genome-wide association studies. IL23R is expressed by CD4+ T cells, monocytes/macrophages, and CD11c+ dendritic cells. IL23 is a pro-inflammatory cytokine which has potential target in the treatment of various autoimmune inflammatory diseases. Duerr et al were the first who identified IL23R as a gene associated with IBDs. They were able to provide evidence for an association in non-Jewish ulcerative colitis (UC) population. In a big German cohort Glas et al (2007) investigated interactions of IBD genes and the influence of IL23R on the phenotype. Eight out of ten single nucleotide polymorphisms (SNPs) showed significant association with UC. The fact that these SNPs were either protective or susceptible in both Crohn's disease and UC suggests similar disease-modifying effects. Recent studies also suggest the SNPs of IL23R to be a predictive factor of response to the therapy, e.g., non-response to mesalazine and corticosteroids as well as higher response rate for azathioprine and infliximab.
Research frontiers
Previous investigations in Hungarian populations verified IL23R to play a role in the development of UC. The present study demonstrated the correlation between the SNPs of IL23R, and the phenotype of UC.
Innovations and breakthroughs
Two of the susceptible SNPs for the development of UC (rs2201841, rs10889677) seem to shift the clinical picture from mild into more severe. The rs10889677 was associated with azathioprine-therapy, suggesting the patients to be refractory to 5-aminosalicylic-acid. The rs7517847 variant showed a protective character (less bowel movements). Rs7517847 has shown to protect the individual from acquiring the disease, assuming a general protective character of this polymorphism.
Applications
These results may allow individual risk stratification, individual pharmacotherapy, and new approaches for medication with targeted therapy. However, more studies are necessary to clarify the exact role of IL23R in the development of IBDs.
